MA26671A1 - COMPOSITION PHARMACEUTIQUE POUVANT eTRE ADMINISTRÉE PAR VOIE ORALE CONTENANT UN INHIBITEUR DE LIPASE GASTRO-INTESTINALE, UN (OU PLUSIEURS) ADDITIF(S) DU GROUPE CONSTITUE PAR LES ÉPAISSISSANTS, ET ÉMULSIFIANTS DE QUALITÉ ALIMENTAIRE MÉDIOCREMENT DIGESTIBLES, MÉDIOCREMENT FERMENTABLES, HYDROPHILES ET OU HYDROCOLLOiDAUX ET DES EXCIPIENTS AUXILIAIRES - Google Patents

COMPOSITION PHARMACEUTIQUE POUVANT eTRE ADMINISTRÉE PAR VOIE ORALE CONTENANT UN INHIBITEUR DE LIPASE GASTRO-INTESTINALE, UN (OU PLUSIEURS) ADDITIF(S) DU GROUPE CONSTITUE PAR LES ÉPAISSISSANTS, ET ÉMULSIFIANTS DE QUALITÉ ALIMENTAIRE MÉDIOCREMENT DIGESTIBLES, MÉDIOCREMENT FERMENTABLES, HYDROPHILES ET OU HYDROCOLLOiDAUX ET DES EXCIPIENTS AUXILIAIRES

Info

Publication number
MA26671A1
MA26671A1 MA25725A MA25725A MA26671A1 MA 26671 A1 MA26671 A1 MA 26671A1 MA 25725 A MA25725 A MA 25725A MA 25725 A MA25725 A MA 25725A MA 26671 A1 MA26671 A1 MA 26671A1
Authority
MA
Morocco
Prior art keywords
hyrodiocredely
hyrodiocredriately
digiously
digious
médiocre
Prior art date
Application number
MA25725A
Other languages
English (en)
Inventor
Manuela Hug
Hans-Peter Maerki
Marcel Meier
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26671A1 publication Critical patent/MA26671A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • General Preparation And Processing Of Foods (AREA)
MA25725A 1998-08-14 1999-08-11 COMPOSITION PHARMACEUTIQUE POUVANT eTRE ADMINISTRÉE PAR VOIE ORALE CONTENANT UN INHIBITEUR DE LIPASE GASTRO-INTESTINALE, UN (OU PLUSIEURS) ADDITIF(S) DU GROUPE CONSTITUE PAR LES ÉPAISSISSANTS, ET ÉMULSIFIANTS DE QUALITÉ ALIMENTAIRE MÉDIOCREMENT DIGESTIBLES, MÉDIOCREMENT FERMENTABLES, HYDROPHILES ET OU HYDROCOLLOiDAUX ET DES EXCIPIENTS AUXILIAIRES MA26671A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98115311 1998-08-14
EP99109516 1999-05-12

Publications (1)

Publication Number Publication Date
MA26671A1 true MA26671A1 (fr) 2004-12-20

Family

ID=26149537

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25725A MA26671A1 (fr) 1998-08-14 1999-08-11 COMPOSITION PHARMACEUTIQUE POUVANT eTRE ADMINISTRÉE PAR VOIE ORALE CONTENANT UN INHIBITEUR DE LIPASE GASTRO-INTESTINALE, UN (OU PLUSIEURS) ADDITIF(S) DU GROUPE CONSTITUE PAR LES ÉPAISSISSANTS, ET ÉMULSIFIANTS DE QUALITÉ ALIMENTAIRE MÉDIOCREMENT DIGESTIBLES, MÉDIOCREMENT FERMENTABLES, HYDROPHILES ET OU HYDROCOLLOiDAUX ET DES EXCIPIENTS AUXILIAIRES

Country Status (19)

Country Link
US (1) US6358522B1 (fr)
EP (1) EP1105122B1 (fr)
JP (1) JP3774118B2 (fr)
KR (1) KR20010079635A (fr)
CN (1) CN1170534C (fr)
AR (1) AR035001A1 (fr)
AT (1) ATE293970T1 (fr)
AU (1) AU761351B2 (fr)
BR (1) BR9912980B1 (fr)
CA (1) CA2340056C (fr)
CO (1) CO5130009A1 (fr)
DE (1) DE69924999T2 (fr)
DK (1) DK1105122T3 (fr)
ES (1) ES2242413T3 (fr)
MA (1) MA26671A1 (fr)
PE (1) PE20000953A1 (fr)
PT (1) PT1105122E (fr)
TR (1) TR200100471T2 (fr)
WO (1) WO2000009122A1 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6264937B1 (en) * 1998-01-09 2001-07-24 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US6299868B1 (en) 1999-07-14 2001-10-09 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US7048917B1 (en) 1998-01-09 2006-05-23 Genzyme Corporation Fat-binding polymers
CA2342625A1 (fr) 1998-09-08 2000-03-16 Smithkline Beecham Corporation Comprimes a base de fibres solubles et d'un derive de lipstatine
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
EP1132389A1 (fr) 2000-03-06 2001-09-12 Vernalis Research Limited Nouveaux dérivés de l'azaindole pour le traitement de l'obésité
AU2001281846B2 (en) * 2000-06-27 2006-04-27 Cheplapharm Arzneimittel Gmbh Method for preparing a composition
NZ523684A (en) * 2000-07-28 2005-04-29 F New pharmaceutical composition
EP1307263B1 (fr) 2000-07-28 2005-04-20 F. Hoffmann-La Roche Ag Nouvelle application d'inhibiteurs de lipase
CN1323661C (zh) 2000-08-09 2007-07-04 霍夫曼-拉罗奇有限公司 脂酶抑制剂的用途
WO2002044152A1 (fr) 2000-10-16 2002-06-06 F. Hoffmann-La Roche Ag Derives d'indoline et leur utilisation en tant que ligands de recepteur 5-ht2
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
WO2002051844A1 (fr) 2000-12-27 2002-07-04 F. Hoffmann-La Roche Ag Derives d'indole et leur utilisation en tant que ligands de recepteurs 5-ht2b et 5-ht2c
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
MXPA03010565A (es) 2001-05-21 2004-03-02 Hoffmann La Roche Derivados de quinolina como ligandos para receptor del neuropeptido y.
US6730319B2 (en) * 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US7049345B2 (en) * 2001-06-29 2006-05-23 Genzyme Corporation Fat-binding polymers
US7041280B2 (en) * 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
US6787558B2 (en) 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
GB0202015D0 (en) 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
BR0307441A (pt) 2002-02-04 2005-01-04 Hoffmann La Roche Compostos, processo para a preparação de um composto, composição farmacêutica, utilização desses compostos, método para o tratamento e profilaxia de enfermidades e método para o tratamento de obesidade
KR100611854B1 (ko) 2002-02-28 2006-08-11 에프. 호프만-라 로슈 아게 신경 펩타이드 ｙ(ｎｐｙ) 수용체 길항제로서의 티아졸유도체
RU2297221C2 (ru) * 2002-04-26 2007-04-20 Ф.Хоффманн-Ля Рош Аг Фармацевтическая композиция, включающая ингибитор липазы и глюкоманнан
MXPA05000131A (es) 2002-07-05 2005-04-11 Hoffmann La Roche Derivados de quinazolina.
CA2493712A1 (fr) 2002-08-07 2004-02-19 F. Hoffmann-La Roche Ag Derives d'aminothiazole pouvant servir d'inhibiteurs de recepteur npy5
NZ537979A (en) 2002-09-12 2007-08-31 Hoffmann La Roche N-substituted-1H-indol-5-propionic acid compounds as PPAR agonists useful for the treatment of diabetes
ATE405560T1 (de) 2002-11-25 2008-09-15 Hoffmann La Roche Indolderivaten
US8372430B2 (en) * 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
GB0314967D0 (en) 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
RU2006107444A (ru) 2003-08-12 2007-09-20 Ф.Хоффманн-Ля Рош Аг (Ch) 2-амино-5-бензоилтиазолы в качестве антагонистов npy
CN100393718C (zh) 2003-08-12 2008-06-11 霍夫曼-拉罗奇有限公司 作为npy拮抗剂的噻唑衍生物
ATE514698T1 (de) 2005-05-03 2011-07-15 Hoffmann La Roche Tetracyclische azapyrazinoindoline als 5-ht2- liganden
SI1897558T1 (sl) * 2005-06-09 2014-03-31 Norgine Bv Trden pripravek 2-heksadeciloksi-6-metil-4h-3,1-benzoksazin-e-on
MX2008002061A (es) 2005-08-18 2008-04-16 Hoffmann La Roche Derivados de tiazolil piperidina utiles como moduladores del receptor h3.
RU2008126391A (ru) 2005-11-30 2010-01-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные 1,5-замещенного индол-2-иламида
ATE507222T1 (de) 2005-11-30 2011-05-15 Hoffmann La Roche 1,1-dioxo-thiomorpholinyl-indolyl-methanon- derivate zur verwendung als h3-modulatoren
DE602006014022D1 (de) 2005-11-30 2010-06-10 Hoffmann La Roche 5-substituierte indol-2-carbonsäureamidderivate
JP2009518351A (ja) 2005-12-09 2009-05-07 エフ．ホフマン−ラ ロシュ アーゲー 肥満症の処置に有用な三環性アミド誘導体
ATE449776T1 (de) 2005-12-15 2009-12-15 Hoffmann La Roche Pyrroloä2,3-cüpyridinderivate
BRPI0619985A2 (pt) 2005-12-16 2011-10-25 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas, métodos para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, de obesidade e de diabetes do tipo ii em um ser humano ou animal e usos dos compostos
US7432255B2 (en) 2006-05-16 2008-10-07 Hoffmann-La Roche Inc. 1H-indol-5-yl-piperazin-1-yl-methanone derivatives
BRPI0711740A2 (pt) 2006-05-30 2011-12-06 Hoffmann La Roche compostos, processo para a sua manufatura,composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, método para o tratamento ou prevenção de obesidade, de diabetes do tipo ii, e uso dos compostos na manufatura de medicamentos
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
US20080146559A1 (en) 2006-12-08 2008-06-19 Li Chen 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
JP5492766B2 (ja) * 2007-05-16 2014-05-14 バックマン・ラボラトリーズ・インターナショナル・インコーポレーテッド 繊維中の有機夾雑物を制御する方法
EP2183237A1 (fr) 2007-07-25 2010-05-12 F. Hoffmann-Roche AG Dérivés d'amide d'acide benzofurane- et benzo[b]thiophène-2-carboxylique et leur utilisation comme modulateurs du récepteur h3 de l'histamine
WO2009044380A2 (fr) 2007-10-05 2009-04-09 Ranbaxy Laboratories Limited Formulations contenant des particules d'orlistat à dimension de particule contrôlée
US20100317642A1 (en) * 2007-10-15 2010-12-16 Inventis Dds Pvt Limited Pharmaceutical composition of orlistat
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
WO2010042499A1 (fr) 2008-10-06 2010-04-15 Banner Pharmacaps, Inc. Solutions stables d'orlistat pour formes galéniques pharmaceutiques
GB201122213D0 (en) * 2011-12-23 2012-02-01 Norgine Bv Compositions
CN104546768B (zh) * 2014-12-30 2017-06-16 重庆植恩药业有限公司 含有脂肪酶抑制剂的咀嚼片组合物及其制备方法
MX386290B (es) * 2016-06-17 2025-03-18 Procter & Gamble Composicion masticable blanda que comprende psyllium
CN112220831A (zh) * 2020-08-07 2021-01-15 天津盛实百草中药科技有限公司 圆苞车前子壳粉在缓解奥利司他副作用中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005195A (en) * 1976-02-12 1977-01-25 The Procter & Gamble Company Compositions for treating hypercholesterolemia
CA1247547A (fr) 1983-06-22 1988-12-28 Paul Hadvary Derives de leucine
US5294451A (en) * 1991-03-29 1994-03-15 Curtice-Burns, Inc. Fat substitute compositions having reduced laxative effects
CA2098167C (fr) * 1992-06-24 2006-12-19 Dorothea Isler Aliments pour humains et animaux contenant un inhibiteur de la lipase
CA2128044C (fr) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Compositions pharmaceutiques comportant un glucosidase et/ou un inhibiteur d'amylase, et un inhibiteur des lipases
JPH09252746A (ja) * 1996-03-22 1997-09-30 Nippon Kankyo Yakuhin Kk 栄養補助食品
JP4202439B2 (ja) * 1996-10-01 2008-12-24 江崎グリコ株式会社 フラボノイド可溶化法、その糖転移法及び高濃度フラボノイド溶液
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions

Also Published As

Publication number Publication date
AU5418599A (en) 2000-03-06
JP2002522491A (ja) 2002-07-23
DK1105122T3 (da) 2005-08-08
EP1105122B1 (fr) 2005-04-27
CA2340056C (fr) 2007-01-09
BR9912980A (pt) 2001-05-08
CN1170534C (zh) 2004-10-13
PT1105122E (pt) 2005-08-31
DE69924999D1 (de) 2005-06-02
BR9912980B1 (pt) 2013-10-22
CA2340056A1 (fr) 2000-02-24
TR200100471T2 (tr) 2001-07-23
ATE293970T1 (de) 2005-05-15
CO5130009A1 (es) 2002-02-27
US6358522B1 (en) 2002-03-19
EP1105122A1 (fr) 2001-06-13
ES2242413T3 (es) 2005-11-01
CN1312713A (zh) 2001-09-12
JP3774118B2 (ja) 2006-05-10
KR20010079635A (ko) 2001-08-22
DE69924999T2 (de) 2006-05-04
PE20000953A1 (es) 2000-09-26
AR035001A1 (es) 2004-04-14
WO2000009122A1 (fr) 2000-02-24
AU761351B2 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
MA26671A1 (fr) COMPOSITION PHARMACEUTIQUE POUVANT eTRE ADMINISTRÉE PAR VOIE ORALE CONTENANT UN INHIBITEUR DE LIPASE GASTRO-INTESTINALE, UN (OU PLUSIEURS) ADDITIF(S) DU GROUPE CONSTITUE PAR LES ÉPAISSISSANTS, ET ÉMULSIFIANTS DE QUALITÉ ALIMENTAIRE MÉDIOCREMENT DIGESTIBLES, MÉDIOCREMENT FERMENTABLES, HYDROPHILES ET OU HYDROCOLLOiDAUX ET DES EXCIPIENTS AUXILIAIRES
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
CA2340052A1 (fr) Compositions pharmaceutiques contenant des inhibiteurs de lipases et du chitosane
HUP9802999A2 (hu) N-propargil-1-amino-indánt tartalmazó gyógyszerkészítmény
NO2013019I2 (no) Aliskiren eller et farmasøytisk akseptabelt salt derav, og hydroklortiazid eller et farmasøytisk akseptabelt salt derav.
NO993519L (no) Fenofibrat farmasöytisk blanding som har höy biotilgjengelighet og fremgangsmÕte for fremstilling av den
MA25284A1 (fr) Composition antioxydante, y compris l'acide de l'acetylene, l-carnitine qui ameliore l'utilisation metabolique du glucose.
EP1762557A3 (fr) Mediateurs lipidiques actives par l'aspirine
BR9908438A (pt) Tabletes de desintegração rápida
DK0693281T3 (da) Farmaceutiske fluoxetinformuleringer
BG103425A (en) Pharmaceutical composition
DE50008336D1 (de) Mehrschichttablette zur verabreichung einer fixen kombination von tramadol und diclofenac
CA2343732A1 (fr) .delta.-lactones .gamma.-phenyl-substituees, leurs analogues, et leurs utilisations
ES2045182T3 (es) Substancias fisiologicamente activas, un proceso para la preparacion de las mismas y composiciones farmaceuticas que las contienen.
WO2005007137A3 (fr) Comprimés contenant de l'ambroxol
EA200200019A1 (ru) Композиция, содержащая щелочную сфингомиелиназу, для применения в качестве диетического препарата, пищевой добавки или фармацевтического продукта
KR920019365A (ko) 디리트로마이신을 함유하는 약학 제형
GB9619660D0 (en) Prevention of gastrointestinal damage
DZ2564A1 (fr) Compositions pharmaceutiques pour le traitement dudiabète sucre et d'états associés.
JPS51128438A (en) An antibacterial drug against fish diseases
ATE224195T1 (de) Glucocorticoide zur behandlung von glomerulonephitis
DZ3103A1 (fr) Nouvelles pyrazolo Ä4,3-EÜdiazépines substituées, compositions pharmaceutiques les contenant, utili sation à titre de médicament et procédés pour leurs préparation.
IT8621097A0 (it) Composizioni farmaceutiche. derivato di timo attivo per via orale, procedimenti per la sua preparazione e relative
WO2001007039A3 (fr) Composition pour prevenir et traiter les affections et les maladies du rein
WO2001022917A8 (fr) Compositions effervescentes comportant du nimesulide